Doxorubicin and taxane combination regimens for metastatic breast cancer: Focus on cardiac effects

https://doi.org/10.1016/S0093-7754(01)90195-2Get rights and content

Abstract

Investigation of the combination of the taxanes with doxorubicin in the treatment of breast cancer has logically progressed, with the ultimate goal of identifying a safe and effective regimen for use in the adjuvant setting. Initial phase II findings of the concurrent doxorubicin/paclitaxel combination resulted in substantial response rates, but at a high cost. A much higher percentage of patients than expected developed anthracycline-induced cardiomyopathy. Subsequent phase II and phase III trials have determined administration schedules of doxorubicin/paclitaxel that reduce the risk for cardiotoxicity. However, the overall response rate is only modestly improved over sequential single-agent therapy or standard doxorubicin-containing combination therapy. The lack of cardiotoxicity with docetaxel, its high antitumor activity, and its linear pharmacokinetics have made it an attractive taxane for combination with doxorubicin. In addition, it is easily administered in the outpatient setting. Phase I/II trials of the combination of doxorubicin/docetaxel resulted in high response rates with a lack of adverse modification of anthracycline-induced cardiomyopathy. These findings have been confirmed in a large phase III randomized trial where overall response rates and time to disease progression were significantly improved, but the incidence of cardiomyopathy was not different for the doxorubicin/docetaxel versus doxorubicin/cyclophosphamide (AC) regimen. Ongoing studies are underway to assess the role of the doxorubicin/ docetaxel combination in the adjuvant setting as primary chemotherapy in the neoadjuvant setting. It is here that the most benefit on survival of breast cancer patients is likely to be shown. At the same time, it is in the adjuvant setting where the absence of potentially late cardiac and other toxicities must be assured.

References (34)

  • JM Nabholtz et al.

    Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing therapy

    J Clin Oncol

    (1999)
  • S Chan et al.

    A phase III study of docetaxel vs. doxorubicin in patients with metastatic breast cancer who have failed an alkylating containing regime

    J Clin Oncol

    (1999)
  • PK Singai et al.

    Doxorubicin-induced cardiomyopathy

    N Engl J Med

    (1998)
  • SS Legha et al.

    Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

    Ann Intern Med

    (1982)
  • DD Von Hoff et al.

    Risk factors for doxorubicin-induced congestive heart failure

    Ann Intern Med

    (1979)
  • EK Rowinsky et al.

    Sequence of taxol and cisplatin: A phase 1 and pharmacologic study

    J Clin Oncol

    (1991)
  • FA Holmes et al.

    Sequence dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

    J Clin Oncol

    (1996)
  • Cited by (27)

    • Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model

      2019, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      No signs of cardiac toxicity were observed for animals in any other groups of treatment. These findings show that the co-encapsulation of PTX and DXR in liposomes leads to a reduction in the toxicity of the combination, enabling the co-administration of PTX and DXR and suggesting that it is more effective than the administration of DXR and PTX treatments separately at different time intervals [55,56]. The co-administration of these agents is nowadays hampered due to the pharmacokinetic interference of PTX in DXR elimination, which leads to enhanced plasma concentrations of DXR and its metabolite, doxorubicinol, also known to be highly cardiotoxic [57,58].

    • MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer

      2017, Clinical Breast Cancer
      Citation Excerpt :

      The taxanes have substantial activity against breast cancer, even after failed treatment with anthracyclines.7 However, the treatment with this regimen presents several adverse effects, including nausea, vomiting, low white blood cell counts, cardiotoxicity, fever, diarrhea, and peripheral neuropathy.8,9 Currently, there are no clinically useful predictive markers to identify patients who are likely to respond to taxanes.10

    View all citing articles on Scopus
    1

    Dr Valero has received research support and honoraria from Aventis and Bristol-Myers Squibb.

    View full text